TAS0314, a novel multi-epitope long peptide vaccine, showed synergistic antitumor immunity with PD-1/PD-L1 blockade in HLA-A2402 mice
Cancer peptide vaccines are a promising cancer immunotherapy that can induce cancer-specific cytotoxic T lymphocytes (CTLs) in tumors. However, recent clinical trials of cancer vaccines have revealed that the efficacy of the vaccines is limited. Targeting single antigens and vaccination with short p...
Gespeichert in:
| Veröffentlicht in: | Scientific reports 2020-10, Vol.10 (1), p.17284-17284, Article 17284 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 17284 |
|---|---|
| container_issue | 1 |
| container_start_page | 17284 |
| container_title | Scientific reports |
| container_volume | 10 |
| creator | Tanaka, Yuki Wada, Hiroshi Goto, Risa Osada, Toshihiro Yamamura, Keisuke Fukaya, Satoshi Shimizu, Atsushi Okubo, Mitsuru Minamiguchi, Kazuhisa Ikizawa, Koichi Sasaki, Eiji Utsugi, Teruhiro |
| description | Cancer peptide vaccines are a promising cancer immunotherapy that can induce cancer-specific cytotoxic T lymphocytes (CTLs) in tumors. However, recent clinical trials of cancer vaccines have revealed that the efficacy of the vaccines is limited. Targeting single antigens and vaccination with short peptides are partly the cause of the poor clinical outcomes. We synthesized a novel multi-epitope long peptide, TAS0314, which induced multiple epitope-specific CTLs in
HLA
knock-in mice. It also showed superior epitope-specific CTL induction and antitumor activity. We also established a combination treatment model of vaccination with PD-1/PD-L1 blockade in
HLA-A*2402
knock-in mice, and it showed a synergistic antitumor effect with TAS0314. Thus, our data indicated that TAS0314 treatment, especially in combination with PD-1/PD-L1 blockade, is a promising therapeutic candidate for cancer immunotherapy. |
| doi_str_mv | 10.1038/s41598-020-74187-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7560884</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2649432235</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-a00b053fe1a15dd56fcb23c21ac76d56c38dc2043410508bfa04c984b4a2e8093</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhSMEolXpC7BAltiwqOn1X-JskEYtUKSRQKKsLcdxZlwSO9jOVPMAvDeGKaWwwAv7Wve7xz46VfWcwGsCTJ4nTkQrMVDADSeywfWj6pgCF5gySh8_qI-q05RuoCxBW07ap9URYyAaqMlx9f169RkY4WdIIx92dkTTMmaH7exymC0ag9-g2c7Z9RbttDHO2zOUtuHW9ijtvY0bl7IzSPvs8jKFiNw0Ld7lPbp1eYs-XWJyXrY1Qd0YzFdddJxHV-sVXlEOFE3O2GfVk0GPyZ7enSfVl3dvry-u8Prj-w8XqzU2vOEZa4AOBBss0UT0vagH01FmKNGmqcvVMNmb4ptxAgJkN2jgppW845paCS07qd4cdOelm2xvrM9Rj2qObtJxr4J26u-Od1u1CTvViBqk5EXg1Z1ADN8Wm7KaXDJ2HLW3YUmKckFkDU1NC_ryH_QmLNEXe4rWvOUlGSYKRQ-UiSGlaIf7zxBQP4NWh6BVCVr9ClrVZejFQxv3I79jLQA7AKm0_MbGP2__R_YHWvuyAQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2649432235</pqid></control><display><type>article</type><title>TAS0314, a novel multi-epitope long peptide vaccine, showed synergistic antitumor immunity with PD-1/PD-L1 blockade in HLA-A2402 mice</title><source>MEDLINE</source><source>Nature Free</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><source>Springer Nature OA Free Journals</source><creator>Tanaka, Yuki ; Wada, Hiroshi ; Goto, Risa ; Osada, Toshihiro ; Yamamura, Keisuke ; Fukaya, Satoshi ; Shimizu, Atsushi ; Okubo, Mitsuru ; Minamiguchi, Kazuhisa ; Ikizawa, Koichi ; Sasaki, Eiji ; Utsugi, Teruhiro</creator><creatorcontrib>Tanaka, Yuki ; Wada, Hiroshi ; Goto, Risa ; Osada, Toshihiro ; Yamamura, Keisuke ; Fukaya, Satoshi ; Shimizu, Atsushi ; Okubo, Mitsuru ; Minamiguchi, Kazuhisa ; Ikizawa, Koichi ; Sasaki, Eiji ; Utsugi, Teruhiro</creatorcontrib><description>Cancer peptide vaccines are a promising cancer immunotherapy that can induce cancer-specific cytotoxic T lymphocytes (CTLs) in tumors. However, recent clinical trials of cancer vaccines have revealed that the efficacy of the vaccines is limited. Targeting single antigens and vaccination with short peptides are partly the cause of the poor clinical outcomes. We synthesized a novel multi-epitope long peptide, TAS0314, which induced multiple epitope-specific CTLs in
HLA
knock-in mice. It also showed superior epitope-specific CTL induction and antitumor activity. We also established a combination treatment model of vaccination with PD-1/PD-L1 blockade in
HLA-A*2402
knock-in mice, and it showed a synergistic antitumor effect with TAS0314. Thus, our data indicated that TAS0314 treatment, especially in combination with PD-1/PD-L1 blockade, is a promising therapeutic candidate for cancer immunotherapy.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-020-74187-6</identifier><identifier>PMID: 33057061</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/250/590/2030 ; 631/67/580 ; Animals ; Antigens ; Antitumor activity ; B7-H1 Antigen - antagonists & inhibitors ; B7-H1 Antigen - genetics ; B7-H1 Antigen - immunology ; Cancer ; Cancer immunotherapy ; Cancer vaccines ; Cancer Vaccines - administration & dosage ; Cancer Vaccines - immunology ; Cell Line, Tumor ; Clinical trials ; Cytotoxicity ; Epitopes ; Female ; Histocompatibility antigen HLA ; HLA-A24 Antigen - genetics ; HLA-A24 Antigen - immunology ; Humanities and Social Sciences ; Humans ; Immunity ; Immunotherapy ; Lymphocytes ; Lymphocytes T ; Mice ; multidisciplinary ; Neoplasms - drug therapy ; Neoplasms - genetics ; Neoplasms - immunology ; PD-1 protein ; PD-L1 protein ; Peptides ; Programmed Cell Death 1 Receptor - antagonists & inhibitors ; Programmed Cell Death 1 Receptor - genetics ; Programmed Cell Death 1 Receptor - immunology ; Science ; Science (multidisciplinary) ; T-Lymphocytes, Cytotoxic - immunology ; Tumors ; Vaccines ; Vaccines, Subunit - administration & dosage</subject><ispartof>Scientific reports, 2020-10, Vol.10 (1), p.17284-17284, Article 17284</ispartof><rights>The Author(s) 2020. corrected publication 2022</rights><rights>The Author(s) 2020. corrected publication 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2020, corrected publication 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-a00b053fe1a15dd56fcb23c21ac76d56c38dc2043410508bfa04c984b4a2e8093</citedby><cites>FETCH-LOGICAL-c474t-a00b053fe1a15dd56fcb23c21ac76d56c38dc2043410508bfa04c984b4a2e8093</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7560884/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7560884/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,41096,42165,51551,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33057061$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tanaka, Yuki</creatorcontrib><creatorcontrib>Wada, Hiroshi</creatorcontrib><creatorcontrib>Goto, Risa</creatorcontrib><creatorcontrib>Osada, Toshihiro</creatorcontrib><creatorcontrib>Yamamura, Keisuke</creatorcontrib><creatorcontrib>Fukaya, Satoshi</creatorcontrib><creatorcontrib>Shimizu, Atsushi</creatorcontrib><creatorcontrib>Okubo, Mitsuru</creatorcontrib><creatorcontrib>Minamiguchi, Kazuhisa</creatorcontrib><creatorcontrib>Ikizawa, Koichi</creatorcontrib><creatorcontrib>Sasaki, Eiji</creatorcontrib><creatorcontrib>Utsugi, Teruhiro</creatorcontrib><title>TAS0314, a novel multi-epitope long peptide vaccine, showed synergistic antitumor immunity with PD-1/PD-L1 blockade in HLA-A2402 mice</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>Cancer peptide vaccines are a promising cancer immunotherapy that can induce cancer-specific cytotoxic T lymphocytes (CTLs) in tumors. However, recent clinical trials of cancer vaccines have revealed that the efficacy of the vaccines is limited. Targeting single antigens and vaccination with short peptides are partly the cause of the poor clinical outcomes. We synthesized a novel multi-epitope long peptide, TAS0314, which induced multiple epitope-specific CTLs in
HLA
knock-in mice. It also showed superior epitope-specific CTL induction and antitumor activity. We also established a combination treatment model of vaccination with PD-1/PD-L1 blockade in
HLA-A*2402
knock-in mice, and it showed a synergistic antitumor effect with TAS0314. Thus, our data indicated that TAS0314 treatment, especially in combination with PD-1/PD-L1 blockade, is a promising therapeutic candidate for cancer immunotherapy.</description><subject>631/250/590/2030</subject><subject>631/67/580</subject><subject>Animals</subject><subject>Antigens</subject><subject>Antitumor activity</subject><subject>B7-H1 Antigen - antagonists & inhibitors</subject><subject>B7-H1 Antigen - genetics</subject><subject>B7-H1 Antigen - immunology</subject><subject>Cancer</subject><subject>Cancer immunotherapy</subject><subject>Cancer vaccines</subject><subject>Cancer Vaccines - administration & dosage</subject><subject>Cancer Vaccines - immunology</subject><subject>Cell Line, Tumor</subject><subject>Clinical trials</subject><subject>Cytotoxicity</subject><subject>Epitopes</subject><subject>Female</subject><subject>Histocompatibility antigen HLA</subject><subject>HLA-A24 Antigen - genetics</subject><subject>HLA-A24 Antigen - immunology</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Immunity</subject><subject>Immunotherapy</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Mice</subject><subject>multidisciplinary</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - genetics</subject><subject>Neoplasms - immunology</subject><subject>PD-1 protein</subject><subject>PD-L1 protein</subject><subject>Peptides</subject><subject>Programmed Cell Death 1 Receptor - antagonists & inhibitors</subject><subject>Programmed Cell Death 1 Receptor - genetics</subject><subject>Programmed Cell Death 1 Receptor - immunology</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>T-Lymphocytes, Cytotoxic - immunology</subject><subject>Tumors</subject><subject>Vaccines</subject><subject>Vaccines, Subunit - administration & dosage</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kc1u1DAUhSMEolXpC7BAltiwqOn1X-JskEYtUKSRQKKsLcdxZlwSO9jOVPMAvDeGKaWwwAv7Wve7xz46VfWcwGsCTJ4nTkQrMVDADSeywfWj6pgCF5gySh8_qI-q05RuoCxBW07ap9URYyAaqMlx9f169RkY4WdIIx92dkTTMmaH7exymC0ag9-g2c7Z9RbttDHO2zOUtuHW9ijtvY0bl7IzSPvs8jKFiNw0Ld7lPbp1eYs-XWJyXrY1Qd0YzFdddJxHV-sVXlEOFE3O2GfVk0GPyZ7enSfVl3dvry-u8Prj-w8XqzU2vOEZa4AOBBss0UT0vagH01FmKNGmqcvVMNmb4ptxAgJkN2jgppW845paCS07qd4cdOelm2xvrM9Rj2qObtJxr4J26u-Od1u1CTvViBqk5EXg1Z1ADN8Wm7KaXDJ2HLW3YUmKckFkDU1NC_ryH_QmLNEXe4rWvOUlGSYKRQ-UiSGlaIf7zxBQP4NWh6BVCVr9ClrVZejFQxv3I79jLQA7AKm0_MbGP2__R_YHWvuyAQ</recordid><startdate>20201014</startdate><enddate>20201014</enddate><creator>Tanaka, Yuki</creator><creator>Wada, Hiroshi</creator><creator>Goto, Risa</creator><creator>Osada, Toshihiro</creator><creator>Yamamura, Keisuke</creator><creator>Fukaya, Satoshi</creator><creator>Shimizu, Atsushi</creator><creator>Okubo, Mitsuru</creator><creator>Minamiguchi, Kazuhisa</creator><creator>Ikizawa, Koichi</creator><creator>Sasaki, Eiji</creator><creator>Utsugi, Teruhiro</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20201014</creationdate><title>TAS0314, a novel multi-epitope long peptide vaccine, showed synergistic antitumor immunity with PD-1/PD-L1 blockade in HLA-A2402 mice</title><author>Tanaka, Yuki ; Wada, Hiroshi ; Goto, Risa ; Osada, Toshihiro ; Yamamura, Keisuke ; Fukaya, Satoshi ; Shimizu, Atsushi ; Okubo, Mitsuru ; Minamiguchi, Kazuhisa ; Ikizawa, Koichi ; Sasaki, Eiji ; Utsugi, Teruhiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-a00b053fe1a15dd56fcb23c21ac76d56c38dc2043410508bfa04c984b4a2e8093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>631/250/590/2030</topic><topic>631/67/580</topic><topic>Animals</topic><topic>Antigens</topic><topic>Antitumor activity</topic><topic>B7-H1 Antigen - antagonists & inhibitors</topic><topic>B7-H1 Antigen - genetics</topic><topic>B7-H1 Antigen - immunology</topic><topic>Cancer</topic><topic>Cancer immunotherapy</topic><topic>Cancer vaccines</topic><topic>Cancer Vaccines - administration & dosage</topic><topic>Cancer Vaccines - immunology</topic><topic>Cell Line, Tumor</topic><topic>Clinical trials</topic><topic>Cytotoxicity</topic><topic>Epitopes</topic><topic>Female</topic><topic>Histocompatibility antigen HLA</topic><topic>HLA-A24 Antigen - genetics</topic><topic>HLA-A24 Antigen - immunology</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Immunity</topic><topic>Immunotherapy</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Mice</topic><topic>multidisciplinary</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - genetics</topic><topic>Neoplasms - immunology</topic><topic>PD-1 protein</topic><topic>PD-L1 protein</topic><topic>Peptides</topic><topic>Programmed Cell Death 1 Receptor - antagonists & inhibitors</topic><topic>Programmed Cell Death 1 Receptor - genetics</topic><topic>Programmed Cell Death 1 Receptor - immunology</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>T-Lymphocytes, Cytotoxic - immunology</topic><topic>Tumors</topic><topic>Vaccines</topic><topic>Vaccines, Subunit - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tanaka, Yuki</creatorcontrib><creatorcontrib>Wada, Hiroshi</creatorcontrib><creatorcontrib>Goto, Risa</creatorcontrib><creatorcontrib>Osada, Toshihiro</creatorcontrib><creatorcontrib>Yamamura, Keisuke</creatorcontrib><creatorcontrib>Fukaya, Satoshi</creatorcontrib><creatorcontrib>Shimizu, Atsushi</creatorcontrib><creatorcontrib>Okubo, Mitsuru</creatorcontrib><creatorcontrib>Minamiguchi, Kazuhisa</creatorcontrib><creatorcontrib>Ikizawa, Koichi</creatorcontrib><creatorcontrib>Sasaki, Eiji</creatorcontrib><creatorcontrib>Utsugi, Teruhiro</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tanaka, Yuki</au><au>Wada, Hiroshi</au><au>Goto, Risa</au><au>Osada, Toshihiro</au><au>Yamamura, Keisuke</au><au>Fukaya, Satoshi</au><au>Shimizu, Atsushi</au><au>Okubo, Mitsuru</au><au>Minamiguchi, Kazuhisa</au><au>Ikizawa, Koichi</au><au>Sasaki, Eiji</au><au>Utsugi, Teruhiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>TAS0314, a novel multi-epitope long peptide vaccine, showed synergistic antitumor immunity with PD-1/PD-L1 blockade in HLA-A2402 mice</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2020-10-14</date><risdate>2020</risdate><volume>10</volume><issue>1</issue><spage>17284</spage><epage>17284</epage><pages>17284-17284</pages><artnum>17284</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>Cancer peptide vaccines are a promising cancer immunotherapy that can induce cancer-specific cytotoxic T lymphocytes (CTLs) in tumors. However, recent clinical trials of cancer vaccines have revealed that the efficacy of the vaccines is limited. Targeting single antigens and vaccination with short peptides are partly the cause of the poor clinical outcomes. We synthesized a novel multi-epitope long peptide, TAS0314, which induced multiple epitope-specific CTLs in
HLA
knock-in mice. It also showed superior epitope-specific CTL induction and antitumor activity. We also established a combination treatment model of vaccination with PD-1/PD-L1 blockade in
HLA-A*2402
knock-in mice, and it showed a synergistic antitumor effect with TAS0314. Thus, our data indicated that TAS0314 treatment, especially in combination with PD-1/PD-L1 blockade, is a promising therapeutic candidate for cancer immunotherapy.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>33057061</pmid><doi>10.1038/s41598-020-74187-6</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2045-2322 |
| ispartof | Scientific reports, 2020-10, Vol.10 (1), p.17284-17284, Article 17284 |
| issn | 2045-2322 2045-2322 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7560884 |
| source | MEDLINE; Nature Free; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection; Free Full-Text Journals in Chemistry; Springer Nature OA Free Journals |
| subjects | 631/250/590/2030 631/67/580 Animals Antigens Antitumor activity B7-H1 Antigen - antagonists & inhibitors B7-H1 Antigen - genetics B7-H1 Antigen - immunology Cancer Cancer immunotherapy Cancer vaccines Cancer Vaccines - administration & dosage Cancer Vaccines - immunology Cell Line, Tumor Clinical trials Cytotoxicity Epitopes Female Histocompatibility antigen HLA HLA-A24 Antigen - genetics HLA-A24 Antigen - immunology Humanities and Social Sciences Humans Immunity Immunotherapy Lymphocytes Lymphocytes T Mice multidisciplinary Neoplasms - drug therapy Neoplasms - genetics Neoplasms - immunology PD-1 protein PD-L1 protein Peptides Programmed Cell Death 1 Receptor - antagonists & inhibitors Programmed Cell Death 1 Receptor - genetics Programmed Cell Death 1 Receptor - immunology Science Science (multidisciplinary) T-Lymphocytes, Cytotoxic - immunology Tumors Vaccines Vaccines, Subunit - administration & dosage |
| title | TAS0314, a novel multi-epitope long peptide vaccine, showed synergistic antitumor immunity with PD-1/PD-L1 blockade in HLA-A2402 mice |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T01%3A47%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=TAS0314,%20a%20novel%20multi-epitope%20long%20peptide%20vaccine,%20showed%20synergistic%20antitumor%20immunity%20with%20PD-1/PD-L1%20blockade%20in%20HLA-A2402%20mice&rft.jtitle=Scientific%20reports&rft.au=Tanaka,%20Yuki&rft.date=2020-10-14&rft.volume=10&rft.issue=1&rft.spage=17284&rft.epage=17284&rft.pages=17284-17284&rft.artnum=17284&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-020-74187-6&rft_dat=%3Cproquest_pubme%3E2649432235%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2649432235&rft_id=info:pmid/33057061&rfr_iscdi=true |